The Efficacy and Safety of 3% Cannabidiol (CBD) Cream in Patients With Epidermolysis Bullosa: A Phase II/III Trial
Stopped The study protocol should to be updated (major updates), following the second Health Canada review /requests. The study has been withdrawn form the REB review and will not be performed at SickKids.
Conditions
- Epidermolysis Bullosa
- Pain
- Itch
Interventions
- DRUG: AVCN583601 (3% Cannabidiol cream)
Sponsor
Elena Pope
Collaborators